Elimination and degradation of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with end-stage renal disease

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Elimination and degradation of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with end-stage renal disease. / Idorn, Thomas; Knop, Filip K; Jørgensen, Morten B; Christensen, Mikkel; Holst, Jens Juul; Hornum, Mads; Feldt-Rasmussen, Bo.

I: The Journal of clinical endocrinology and metabolism, Bind 99, Nr. 7, jc20133809, 08.04.2014, s. 2457-66.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Idorn, T, Knop, FK, Jørgensen, MB, Christensen, M, Holst, JJ, Hornum, M & Feldt-Rasmussen, B 2014, 'Elimination and degradation of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with end-stage renal disease', The Journal of clinical endocrinology and metabolism, bind 99, nr. 7, jc20133809, s. 2457-66. https://doi.org/10.1210/jc.2013-3809

APA

Idorn, T., Knop, F. K., Jørgensen, M. B., Christensen, M., Holst, J. J., Hornum, M., & Feldt-Rasmussen, B. (2014). Elimination and degradation of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with end-stage renal disease. The Journal of clinical endocrinology and metabolism, 99(7), 2457-66. [jc20133809]. https://doi.org/10.1210/jc.2013-3809

Vancouver

Idorn T, Knop FK, Jørgensen MB, Christensen M, Holst JJ, Hornum M o.a. Elimination and degradation of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with end-stage renal disease. The Journal of clinical endocrinology and metabolism. 2014 apr 8;99(7):2457-66. jc20133809. https://doi.org/10.1210/jc.2013-3809

Author

Idorn, Thomas ; Knop, Filip K ; Jørgensen, Morten B ; Christensen, Mikkel ; Holst, Jens Juul ; Hornum, Mads ; Feldt-Rasmussen, Bo. / Elimination and degradation of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with end-stage renal disease. I: The Journal of clinical endocrinology and metabolism. 2014 ; Bind 99, Nr. 7. s. 2457-66.

Bibtex

@article{ccc6076b5299441aa8fc38ce89bed451,
title = "Elimination and degradation of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with end-stage renal disease",
abstract = "Context: The impact of the kidneys in elimination and degradation of intact incretin hormones and their truncated metabolites is unclear. Objective: To evaluate elimination and degradation of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) in patients with dialysis-dependent kidney failure. Design and study subjects: Twelve non-diabetic patients treated with chronic hemodialysis and 12 control subjects were examined in a double-blinded, randomized, matched, observational study. Setting: Department of Nephrology, Rigshospitalet, University of Copenhagen, Denmark. Intervention: Over 4 separate study days, synthetic human GIP or GLP-1 was infused with or without concurrent inhibition of DPP-4 using sitagliptin or placebo. Main outcome measures: Plasma concentrations of glucose, insulin, glucagon, and intact and total forms of GLP-1 or GIP were measured repeatedly. Plasma half-life (T1/2), metabolic clearance rate (MCR), area under curve and volume of distribution for intact and metabolite levels of GLP-1 and GIP were calculated. Results: Fasting concentrations of intact GLP-1 and GIP were increased in dialysis patients (P < 0.001), whereas fasting levels of GLP-1 and GIP metabolites did not differ between groups (P > 0.738). MCRs of intact GLP-1 and GIP, and the GLP-1 metabolite were reduced in dialysis patients on the placebo day (P < 0.009), while T1/2 of intact and metabolite forms of GLP-1 and GIP were comparable between groups (P > 0.121). Conclusions: Unexpectedly, degradation and elimination of the intact and metabolite forms of GLP-1 and GIP appeared preserved, although reduced, in patients with dialysis-dependent kidney failure.",
author = "Thomas Idorn and Knop, {Filip K} and J{\o}rgensen, {Morten B} and Mikkel Christensen and Holst, {Jens Juul} and Mads Hornum and Bo Feldt-Rasmussen",
year = "2014",
month = "4",
day = "8",
doi = "10.1210/jc.2013-3809",
language = "English",
volume = "99",
pages = "2457--66",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "Oxford University Press",
number = "7",

}

RIS

TY - JOUR

T1 - Elimination and degradation of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with end-stage renal disease

AU - Idorn, Thomas

AU - Knop, Filip K

AU - Jørgensen, Morten B

AU - Christensen, Mikkel

AU - Holst, Jens Juul

AU - Hornum, Mads

AU - Feldt-Rasmussen, Bo

PY - 2014/4/8

Y1 - 2014/4/8

N2 - Context: The impact of the kidneys in elimination and degradation of intact incretin hormones and their truncated metabolites is unclear. Objective: To evaluate elimination and degradation of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) in patients with dialysis-dependent kidney failure. Design and study subjects: Twelve non-diabetic patients treated with chronic hemodialysis and 12 control subjects were examined in a double-blinded, randomized, matched, observational study. Setting: Department of Nephrology, Rigshospitalet, University of Copenhagen, Denmark. Intervention: Over 4 separate study days, synthetic human GIP or GLP-1 was infused with or without concurrent inhibition of DPP-4 using sitagliptin or placebo. Main outcome measures: Plasma concentrations of glucose, insulin, glucagon, and intact and total forms of GLP-1 or GIP were measured repeatedly. Plasma half-life (T1/2), metabolic clearance rate (MCR), area under curve and volume of distribution for intact and metabolite levels of GLP-1 and GIP were calculated. Results: Fasting concentrations of intact GLP-1 and GIP were increased in dialysis patients (P < 0.001), whereas fasting levels of GLP-1 and GIP metabolites did not differ between groups (P > 0.738). MCRs of intact GLP-1 and GIP, and the GLP-1 metabolite were reduced in dialysis patients on the placebo day (P < 0.009), while T1/2 of intact and metabolite forms of GLP-1 and GIP were comparable between groups (P > 0.121). Conclusions: Unexpectedly, degradation and elimination of the intact and metabolite forms of GLP-1 and GIP appeared preserved, although reduced, in patients with dialysis-dependent kidney failure.

AB - Context: The impact of the kidneys in elimination and degradation of intact incretin hormones and their truncated metabolites is unclear. Objective: To evaluate elimination and degradation of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) in patients with dialysis-dependent kidney failure. Design and study subjects: Twelve non-diabetic patients treated with chronic hemodialysis and 12 control subjects were examined in a double-blinded, randomized, matched, observational study. Setting: Department of Nephrology, Rigshospitalet, University of Copenhagen, Denmark. Intervention: Over 4 separate study days, synthetic human GIP or GLP-1 was infused with or without concurrent inhibition of DPP-4 using sitagliptin or placebo. Main outcome measures: Plasma concentrations of glucose, insulin, glucagon, and intact and total forms of GLP-1 or GIP were measured repeatedly. Plasma half-life (T1/2), metabolic clearance rate (MCR), area under curve and volume of distribution for intact and metabolite levels of GLP-1 and GIP were calculated. Results: Fasting concentrations of intact GLP-1 and GIP were increased in dialysis patients (P < 0.001), whereas fasting levels of GLP-1 and GIP metabolites did not differ between groups (P > 0.738). MCRs of intact GLP-1 and GIP, and the GLP-1 metabolite were reduced in dialysis patients on the placebo day (P < 0.009), while T1/2 of intact and metabolite forms of GLP-1 and GIP were comparable between groups (P > 0.121). Conclusions: Unexpectedly, degradation and elimination of the intact and metabolite forms of GLP-1 and GIP appeared preserved, although reduced, in patients with dialysis-dependent kidney failure.

U2 - 10.1210/jc.2013-3809

DO - 10.1210/jc.2013-3809

M3 - Journal article

C2 - 24712563

VL - 99

SP - 2457

EP - 2466

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 7

M1 - jc20133809

ER -

ID: 117851453